K2 Principal Fund, L.P. Tcr2 Therapeutics Inc. Transaction History

K2 Principal Fund, L.P.

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2022 Nov 14, 2022	BUY	$1.86 - $3.75 $1.53 Million - $3.08 Million	821,754 Added 76.22%	1,899,824 $3.42 Million
Q2 2022 Aug 12, 2022	BUY	$2.11 - $2.94 $2.27 Million - $3.17 Million	1,078,070 New	1,078,070 $3.13 Million

Ticker TCRR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,606,400
Description
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical tria...

Get notified when there are updates to the investment portfolio of K2 Principal Fund, L.P., based on Form 13F filings with the SEC.

Stay updated on K2 Principal Fund, L.P. with notifications on news.